CytoMed Therapeutics (US:GDTC)2026-03-31 12:01Financial Position - As of December 31, 2025, the company had cash and bank balances of S$2.10 million, down from S$4.97 million in 2024[757]. - As of December 31, 2025, the company had total contractual obligations of S$494,010 for bank borrowings and S$79,821 for lease liabilities[773]. Cash Flow - For the year ended December 31, 2025, net cash used in operating activities was S$3.70 million, primarily due to a loss of S$4.00 million[761]. - The company generated net cash from financing activities of S$208,648 in 2025, mainly from the issuance of ordinary shares[767]. - Total net cash used in investing activities for the year ended December 31, 2025, was S$929,283, primarily from proceeds of S$700,000 from dilution of interest in a subsidiary[764]. Revenue and Operations - The company has not generated any revenue from approved commercial sales and expects this to continue for the foreseeable future[756]. - The company plans to fund its operations through various sources, including net proceeds from its ATM offering and other equity and debt financings[757]. Research and Development - The company incurred R&D expenses that include employees' benefits and laboratory supplies, with estimates made for accrued expenses[777][778]. - The company anticipates increased costs associated with operating as a public listed company and ongoing R&D activities[768]. Compliance and Growth Status - The company is classified as an "emerging growth company" and has elected to delay the adoption of certain accounting standards[783]. - The Company will maintain its emerging growth status until it exceeds U.S.$1.235 billion in annual revenue or meets other specified criteria[784]. - The Company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay compliance with certain accounting standards until they apply to private companies[783]. Share Issuance - On January 14, 2026, the Company issued 4,400 ordinary shares under its ATM offering program, generating gross proceeds of approximately U.S.$6,000[786].